Trials / NCT06319872
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Recruiting now Phase 1 Drug / neuroprotection
- Sponsor
- University of Rochester
- Treatment
- Oral disulfiram
- Gene
- Not stated
- Conditions
- Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Ages
- 18 Years to no upper limit
- Enrollment
- 15 participants
- Started
- 2025-05-19
- Main results expected
- 2029-05-19
- Results posted
- Not yet
- Record last updated
- 2026-09-16
What the study is testing
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
Where it runs
United States (1)
- Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York (recruiting now)